Cargando…

Chemotherapy options versus “novel” therapies: how should we treat patients with malignant pleural mesothelioma

Today there are several options for the treatment of patients with malignant pleural mesothelioma (MPM). The therapeutic arsenal has expanded from only chemotherapy with or without surgery in selected cases to a variety of new compounds that target the malignant cell or its micro-environment. Immuno...

Descripción completa

Detalles Bibliográficos
Autores principales: Disselhorst, Maria J., Baas, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082258/
https://www.ncbi.nlm.nih.gov/pubmed/32206573
http://dx.doi.org/10.21037/tlcr.2020.01.16
_version_ 1783508312810061824
author Disselhorst, Maria J.
Baas, Paul
author_facet Disselhorst, Maria J.
Baas, Paul
author_sort Disselhorst, Maria J.
collection PubMed
description Today there are several options for the treatment of patients with malignant pleural mesothelioma (MPM). The therapeutic arsenal has expanded from only chemotherapy with or without surgery in selected cases to a variety of new compounds that target the malignant cell or its micro-environment. Immunotherapy has been the latest achievement and now single arm and randomized studies are being presented. A renewed interest has occurred in the combination of surgery, chemotherapy and radiation therapy. In this review we present the available data on previous and running studies and try to give a recommendation how to select the best patient for the most optimal therapy.
format Online
Article
Text
id pubmed-7082258
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-70822582020-03-23 Chemotherapy options versus “novel” therapies: how should we treat patients with malignant pleural mesothelioma Disselhorst, Maria J. Baas, Paul Transl Lung Cancer Res Review Article Today there are several options for the treatment of patients with malignant pleural mesothelioma (MPM). The therapeutic arsenal has expanded from only chemotherapy with or without surgery in selected cases to a variety of new compounds that target the malignant cell or its micro-environment. Immunotherapy has been the latest achievement and now single arm and randomized studies are being presented. A renewed interest has occurred in the combination of surgery, chemotherapy and radiation therapy. In this review we present the available data on previous and running studies and try to give a recommendation how to select the best patient for the most optimal therapy. AME Publishing Company 2020-02 /pmc/articles/PMC7082258/ /pubmed/32206573 http://dx.doi.org/10.21037/tlcr.2020.01.16 Text en 2020 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Review Article
Disselhorst, Maria J.
Baas, Paul
Chemotherapy options versus “novel” therapies: how should we treat patients with malignant pleural mesothelioma
title Chemotherapy options versus “novel” therapies: how should we treat patients with malignant pleural mesothelioma
title_full Chemotherapy options versus “novel” therapies: how should we treat patients with malignant pleural mesothelioma
title_fullStr Chemotherapy options versus “novel” therapies: how should we treat patients with malignant pleural mesothelioma
title_full_unstemmed Chemotherapy options versus “novel” therapies: how should we treat patients with malignant pleural mesothelioma
title_short Chemotherapy options versus “novel” therapies: how should we treat patients with malignant pleural mesothelioma
title_sort chemotherapy options versus “novel” therapies: how should we treat patients with malignant pleural mesothelioma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082258/
https://www.ncbi.nlm.nih.gov/pubmed/32206573
http://dx.doi.org/10.21037/tlcr.2020.01.16
work_keys_str_mv AT disselhorstmariaj chemotherapyoptionsversusnoveltherapieshowshouldwetreatpatientswithmalignantpleuralmesothelioma
AT baaspaul chemotherapyoptionsversusnoveltherapieshowshouldwetreatpatientswithmalignantpleuralmesothelioma